



HHS Public Access

Author manuscript

Circulation. Author manuscript; available in PMC 2023 November 29.

Published in final edited form as:

Circulation. 2022 November 29; 146(22): 1694–1711. doi:10.1161/CIRCULATIONAHA.121.058777.

Hippo-Yap signaling maintains sinoatrial node homeostasis

Mingjie Zheng, PhD,

Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston

Rich G. Li, PhD,

Texas Heart Institute, Houston, Texas, USA

Jia Song, MD,

Department of Medicine (Section of Cardiovascular Research), Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA

Xiaolei Zhao, PhD,

Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston

Li Tang, MS,

Hunan Provincial Key Lab on Bioinformatics, School of Computer Science and Engineering, Central South University, Changsha, Hunan, China

Shannon Erhardt, MS,

Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston

MD Anderson Cancer Center and UTHealth Graduate School of Biomedical Sciences, The University of Texas, Houston, Texas, USA

Wen Chen, BS,

Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston

Bao H. Nguyen, BS,

Department of Molecular Physiology and Biophysics, Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA

Xiao Li, PhD,

Texas Heart Institute, Houston, Texas, USA

Min Li, PhD,

Correspondence Jun Wang, PhD, Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Texas 77030, USA. jun.wang@uth.tmc.edu.

Disclosures

None.

Supplemental Materials

Supplemental Methods

Figures S1–S8

Table S1

Hunan Provincial Key Lab on Bioinformatics, School of Computer Science and Engineering, Central South University, Changsha, Hunan, China

Jianxin Wang, PhD,

Hunan Provincial Key Lab on Bioinformatics, School of Computer Science and Engineering, Central South University, Changsha, Hunan, China

Sylvia M. Evans, PhD,

Skaggs School of Pharmacy and Pharmaceutical Sciences, Departments of Pharmacology and Medicine, University of California at San Diego, La Jolla, CA 92093, USA

Vincent M. Christoffels, PhD,

Medical Biology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Na Li, PhD,

Department of Medicine (Section of Cardiovascular Research), Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX, USA

Jun Wang, PhD

Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston

MD Anderson Cancer Center and UTHealth Graduate School of Biomedical Sciences, The University of Texas, Houston, Texas, USA

Abstract

BACKGROUND: The sinoatrial node (SAN) functions as the pacemaker of the heart, initiating rhythmic heartbeats. Despite its importance, the SAN is one of the most poorly understood cardiac entities because of its small size and complex composition and function. The Hippo signaling pathway is a molecular signaling pathway fundamental to heart development and regeneration. Although abnormalities of the Hippo pathway are associated with cardiac arrhythmias in human patients, this pathway's role in the SAN is unknown.

METHODS: We investigated key regulators of the Hippo pathway in SAN pacemaker cells by conditionally inactivating the Hippo signaling kinases *Lats1* and *Lats2* using the tamoxifen-inducible, cardiac conduction system (CCS)-specific Cre driver *Hcn4^{CreERT2}* with *Lats1* and *Lats2* conditional knockout (CKO) alleles. In addition, the Hippo signaling effectors *Yap* and *Taz* were conditionally inactivated in the SAN. To determine the function of Hippo signaling in the SAN and other CCS components, we conducted a series of physiologic and molecular experiments including telemetry electrocardiogram recording, echocardiography, Masson's Trichrome staining, calcium imaging, immunostaining, RNAscope, Cleavage Under Targets and Tagmentation (CUT&Tag) sequencing using antibodies against Yap1 or H3K4me3, quantitative real-time PCR, and Western blotting. We also performed comprehensive bioinformatics analyses of various datasets.

RESULTS: We found that *Lats1/2* inactivation caused severe sinus node dysfunction. Compared with the controls, *Lats1/2* CKO mutants exhibited dysregulated calcium handling and increased fibrosis in the SAN, indicating that *Lats1/2* function through both cell-autonomous and non-

cell-autonomous mechanisms. It is notable that the *Lats1/2* conditional knockout phenotype was rescued by genetic deletion of *Yap* and *Taz* in the cardiac conduction system. These rescued mice had normal sinus rhythm and reduced fibrosis of the SAN, indicating that *Lats1/2* function through *Yap* and *Taz*. Cleavage Under Targets and Tagmentation sequencing data showed that *Yap* potentially regulates genes critical for calcium homeostasis such as *Ryr2* and genes encoding paracrine factors important in intercellular communication and fibrosis induction such as *Tgfb1* and *Tgfb3*. Consistent with this, *Lats1/2* CKO mutants had decreased *Ryr2* expression and increased *Tgfb1* and *Tgfb3* expression compared with control mice.

CONCLUSIONS: We reveal, for the first time to our knowledge, that the canonical Hippo-Yap pathway plays a pivotal role in maintaining SAN homeostasis.

Keywords

Hippo signaling; sinus node dysfunction; fibrosis; TGF- β ; calcium homeostasis

INTRODUCTION

The cardiac conduction system (CCS) initiates and propagates electrical depolarization, which coordinates the synchronized contraction of the cardiac muscle. Disturbances in the CCS give rise to cardiac arrhythmias, a major cause of morbidity and mortality worldwide.¹⁻³ The CCS consists of the sinoatrial node (SAN, or sinus node), atrioventricular node (AVN), bundle of His, bundle branches, and Purkinje fibers.^{4, 5} The SAN is the primary pacemaker structure of the heart, and is a heterogeneous tissue characterized by clusters of pacemaker cells (PCs) encompassed within fibrotic components including collagens, elastin, and cardiac fibroblasts (CFs).⁶ PCs are characterized as highly specialized cardiomyocytes, which can generate electrical impulses to spontaneously and directly control the heart rate.^{7, 8} SAN intranodal fibrotic tissue provides important structural and functional integrity for PCs, along with electrically insulating PCs from the surrounding atrial myocardium to efficiently regulate normal sinus rhythm.^{9, 10} However, increased SAN fibrosis under pathologic conditions may cause cardiac arrhythmias such as tachycardia-bradycardia arrhythmias, cardiac arrest, atrial fibrillation, and ventricular arrhythmias. The function of the SAN is highly sensitive to changes in ionic currents, such as those regulated by intracellular calcium signaling¹¹ and energy metabolism¹² in the adult heart. In addition, the risk for sinus node dysfunction (SND, also known as sick sinus syndrome) increases with other factors including aging, hypertension, and concomitant conduction disease.¹³ The incidence of SND is predicted to double over the next 50 years.¹⁴ Therefore, understanding the molecular machinery controlling SAN homeostasis in adulthood has considerable clinical significance.

Hippo signaling is a highly conserved kinase cascade that plays critical roles in cardiac development, regeneration, and homeostasis. When Hippo signaling is active, the downstream Hippo effectors *Yap/Taz* are phosphorylated by the Hippo core kinases *Lats1/2*. Phosphorylated *Yap/Taz* are retained in the cytoplasm and are eventually degraded. When Hippo signaling is off, *Yap/Taz* act as transcriptional cofactors that can translocate into the nucleus and interact with other transcription factors such as TEA domain transcription factor family members (TEADs) to regulate gene expression.^{15, 16} Hippo signaling plays

critical roles during both embryonic and postnatal stages, including the regulation of cardiomyocyte proliferation and renewal.^{17–23} According to the DECIPHER (Database of genomic variation and Phenotype in Humans using Ensembl Resources) database, patients with sequence variants in Hippo pathway components had cardiac defects and arrhythmias. Altered Hippo pathway activity has been found in patients with arrhythmogenic and hypertrophic cardiomyopathy heart failure.^{20, 24, 25} Compared with normal human heart samples, myocardial samples from patients with arrhythmogenic cardiomyopathy had greater Hippo signaling activity and increased phosphorylated YAP level.²⁴ Analysis of RNA-seq data indicated that expression of *Mst1*, a core kinase of Hippo signaling and an upstream regulator of *Lats1/2*, was significantly less in the SAN of failing human hearts than in SAN of donor hearts without heart failure or a history of arrhythmia.²⁶ Recent bioinformatics analysis of gene expression profiles predicted that Hippo signaling was the most significantly enriched pathway in the left atrium of atrial fibrillation patients.²⁷ These studies suggest the potential role of Hippo signaling in the CCS. Hippo signaling has been studied in different cardiac contexts, yet its function in the CCS has not been investigated.

To uncover the function of Hippo signaling in the SAN, we conditionally deleted *Lats1* and *Lats2* in the CCS in the *Hcn4^{CreERT2}; Lats1/2^{flox/flox}* (*Lats1/2* CKO) mouse model. *Hcn4^{CreERT2}* is a tamoxifen-inducible CCS-specific Cre,²⁸ which is specifically expressed in the developing and adult SAN and in the other components of the conduction system from fetal stages onward. We found that *Lats1/2* CKO mice developed cardiac conduction disorders such as sinus pauses, atrioventricular (AV) blocks, irregular RR intervals, and abnormal P-waves. Furthermore, *Lats1/2* deletion disrupted the intrinsic calcium homeostasis of PCs, making their spontaneous firing rate irregular. We also found that the absence of *Lats1/2* increased SAN fibrosis by non-cell-autonomous fibroblast proliferation; however, PCs in both control and *Lats1/2* CKO mice were not proliferative. We further determined that *Lats1/2* function through *Yap* and *Taz* and performed CUT&Tag sequencing to uncover Yap target genes in the SAN. We found that Hippo-Yap signaling regulates the key calcium homeostasis genes such as sarcoplasmic reticulum (SR) calcium channel *Ryr2* (encoding ryanodine receptor type 2, RyR2) and important genes for cell communication and fibrosis induction such as *Tgfb1* and *Tgfb3*. For the first time to our knowledge, we show that Hippo-Yap signaling is required for maintaining SAN homeostasis through both cell-autonomous and non-cell-autonomous mechanisms.

METHODS

All animal studies and procedures were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals and were approved by The University of Texas Health Science Center at Houston Institutional Animal Care and Use Committee. Detailed methods and supporting data are available in the Supplementary Material. Study materials are available from the corresponding author upon reasonable request.

Mice

Hcn4^{CreERT2},²⁸ *Lats1^{flox/flox}*,¹⁷ *Lats2^{flox/flox}*,¹⁷ *Yap^{flox/flox}*,¹⁹ and *Taz^{flox/flox}*,¹⁹ mouse lines were previously described. Six- to eight-week-old mice were intraperitoneally injected with 150 mg tamoxifen (10 mg/ml) per day for 2 days to induce *Hcn4^{CreERT2}* activity.

Telemetry Electrocardiography

Telemetry electrocardiograms (ECGs) were recorded over 24 hours in conscious and ambulatory mice using telemetry transmitters ETA-F10 (Data Sciences International) as previously described.²⁹

Echocardiography

Echocardiography was performed on anesthetized mice as previously described³⁰ by using a VisualSonics Vevo 2100 system with a 550-s probe.

Confocal Ca²⁺ imaging of PCs

SAN tissues were isolated as previously described.¹² Confocal Ca²⁺ imaging studies were performed in isolated PCs from SAN tissues as previously described.^{31, 32}

CUT&Tag and sequencing data analysis

CUT&Tag assays in nuclei from SAN tissues were performed as previously described³³ by separately using anti-H3K4me3 and anti-Yap1 antibodies. The CUT&Tag sequencing (GSE202641) raw reads were aligned by using Bowtie2³⁴ and were further processed with Picard and Samtools.³⁵ Cut&Tag signals in the genome were visualized by using the bamCoverage module of deepTools.³⁶ SEACR³⁷ was used to call peaks, and peaks were annotated with Homer.³⁸ Metascape was used for gene ontology analysis.³⁹ For conserved sequence analysis, the phastCons60way score⁴⁰ file of mm10 was downloaded from the UCSC Genome Browser.

ATAC-seq data processing and analysis

Raw ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing) reads of PCd and right atrial cardiomyocytes ATAC-seq data (GSE148515⁴¹) were mapped to the mm10 build of the mouse genome using BWA with default settings. For SAN-like pacemaker cells and ventricle-like cardiomyocytes ATAC-seq data (GSE146044⁴²), raw ATAC-seq reads were mapped to the hg19 build of the mouse genome using BWA with default settings.

Statistical Analysis

Quantitative data are presented as the mean±SEM. All statistical tests, error bars, P-values, and n numbers of sample sizes and replicates are reported in the corresponding figure legends.

RESULTS

***Lats1* and *Lats2* deletion in the CCS results in cardiac conduction disorders**

To determine whether Hippo signaling functionally affects the CCS, we generated inducible CCS-specific knockout models of the Hippo signaling kinases *Lats1* and *Lats2* by intercrossing the floxed *Lats1/2* (*Lats1*^{*flox/flox*}; *Lats2*^{*flox/flox*}) mice with the inducible CCS-specific Cre *Hcn4*^{*CreERT2*} mice.²⁸ Mice were treated with tamoxifen at 6–8 weeks of age (Figure 1A). Both *Hcn4*^{*CreERT2*} and *Lats1/2*^{*flox/flox*} mice were used as controls. Yap is an effector of Hippo signaling and is phosphorylated by *Lats1* and *Lats2* when Hippo signaling is active.^{43–45} To detect Hippo signaling activity in the SAN, we co-stained phosphorylated (inactive) Yap-Ser127 (pYap) and the PC marker *Hcn4* in sections of SAN tissue from both control and *Lats1/2* CKO mice.^{46–48} Compared with control SANs (Figure 1B), SANs of *Lats1/2* CKO mice had decreased pYap levels in *Hcn4*-positive PCs (Figure 1C). Consistent with this, active Yap (aYap) protein level was greater in the PC nuclei of *Lats1/2* CKO mice (Figure 1E) than in those of controls (Figure 1D). These data indicated efficient CCS-specific inactivation of *Lats1/2* in *Lats1/2* CKO mice.

To further elucidate the functional role of Hippo signaling in the CCS, we obtained telemetry ECG recordings in both control and *Lats1/2* CKO mice with implanted telemetry transmitters for over 24 hours. Before tamoxifen treatment, we recorded ECGs from controls (including *Hcn4*^{*CreERT2*} and *Lats1/2*^{*flox/flox*} mice) and *Lats1/2* CKO mice and found no obvious ECG differences between these mice. At 8 days after tamoxifen injection, the most frequently observed phenotypes in *Lats1/2* CKO mice were cardiac conduction disorders including AV block and SND, which manifested as lower heart rates and longer RR intervals than in control mice (Figure 1F–1G). Poincaré plot analysis of the RR intervals demonstrated tremendous beat-to-beat variation in *Lats1/2* CKO mice (Figure 1H–1I). The heart rate was lower (Figure 1J), and the average RR interval was significantly longer in *Lats1/2* CKO mice (Figure 1K). In contrast, average P duration, PR interval, QRS complex duration, and QTc duration were not significantly different between control and *Lats1/2* CKO mice (Figure S1J–S1M), suggesting that atrial and ventricular conduction and the other components of the CCS were less affected by *Lats1/2* deficiency. Together, these findings indicate that the CCS-specific deletion of *Lats1/2* disrupts the function of the SAN.

***Lats1* and *Lats2* deficiency in the CCS does not cause altered heart contractile function**

Hippo signaling is known to play an important role in regulating cardiomyocyte proliferation and heart size in mouse embryos, as well as cardiomyocyte size in adult mice.^{21, 49–51} Therefore, we further determined whether *Lats1/2* deletion in the CCS alters heart size, SAN PC size, and general cardiac function. No obvious difference was observed in the size of *Lats1/2* CKO hearts and control hearts (Figure S1A–S1B). Co-staining of wheat germ agglutinin (WGA, plasma membrane marker) and *Hcn4* (Figure S1C–S1D) indicated no significant difference in PC size between *Lats1/2* CKO and control mice (Figure S1E). Likewise, echocardiography data showed no obvious between-group differences in cardiac contractile function and dimensions (Figure S1F–S1I). Further analysis of echocardiographic measurements indicated no significant differences between control and *Lats1/2* CKO in parameters such as left ventricle internal diameter, left ventricle posterior

wall thickness, left ventricle volume, stroke volume, cardiac output, ejection fraction, and fractional shortening (Table S1). Together, these results indicated that the CCS-specific deletion of *Lats1/2* did not affect overall heart size, pacemaker cell size, or cardiac function, suggesting that phenotypes caused by *Lats1/2* deletion were intrinsic to the CCS rather than secondary effects.

Loss of *Lats1/2* in PCs promotes fibrosis in the SAN

To investigate whether SND in *Lats1/2* CKO mice was associated with structural abnormalities of the SAN region, we evaluated collagen deposition and fibrosis in the SAN region. Masson's Trichrome staining revealed that compared with control SANs (Figure 2A), *Lats1/2* CKO SANs (Figure 2B) exhibited an increase in blue-stained collagen content, although no obvious differences were observed between control and *Lats1/2* CKO mice in other cardiac components such as the right atria, cardiac valves, and ventricular septal regions (Figure S2A–S2B). We further performed immunohistochemistry (IHC) experiments to label the extracellular matrix protein collagen 1 (Col1a1) in tissue sections of control and *Lats1/2* CKO mice and used the co-staining of *Hcn4* to indicate the SAN region. Col1a1 levels were significantly greater in SANs of *Lats1/2* CKO samples than in those of controls (Figure 2C–2E), indicating that *Lats1/2* deficiency increased collagen deposition. Expression level of the fibroblast marker vimentin (Vim) was also higher in the SAN region of *Lats1/2* CKO hearts than in that of control hearts (Figure 2F–2G). These data revealed fibrotic remodeling and increased fibrosis in the SAN caused by the deletion of *Lats1/2* in PCs.

Loss of *Lats1/2* promotes fibroblast but not pacemaker cell proliferation in the SAN

Hippo signaling has a well-known and critical role in cell proliferation. Therefore, to determine the impact on proliferation caused by loss of *Lats1/2*, we injected control and *Lats1/2* CKO mice with 5-ethynyl-2'-deoxyuridine (EdU) for four consecutive days before the heart was harvested at 8 days after tamoxifen injection. EdU signal was barely detectable in cardiac troponin-T (cTnT)-positive PCs of both control and *Lats1/2* CKO hearts, indicating that PCs were not proliferative after *Lats1/2* deletion (Figure 2F–2H). However, EdU labeling indicated that vimentin-positive fibroblast cells were significantly more proliferative in the SAN region of *Lats1/2* CKO hearts than in control hearts (Figure 2F–2H). To examine expression of fibrosis-regulated genes, we isolated RNA from dissected SAN tissues of control and *Lats1/2* CKO mouse hearts. qRT-PCR analysis revealed that mRNA expression of the fibrosis-associated genes *Col1a1*, *Vimentin*, *Acta2* (encoding alpha-smooth muscle actin, aSMA) and *Periostin* (*Postn*) were upregulated in *Lats1/2* CKO SANs compared to control SANs (Figure 2I–2L). These data suggested that *Lats1/2* deletion in the CCS increased SAN fibrosis and non-cell-autonomous fibroblast proliferation.

Lats1/2 deficiency disrupts calcium homeostasis in SAN PCs

Spontaneous beating and rhythmic electrical impulses of the SAN are regulated by the I_f -dependent voltage membrane clock and the intracellular Ca^{2+} clock, which is controlled by the localized subsarcolemmal Ca^{2+} release via RyR2 on the SR.^{52, 53} Therefore to study potential mechanisms responsible for SND at the cellular level, we evaluated cellular Ca^{2+} activity by performing confocal Ca^{2+} imaging in isolated PCs of control (Figure 3A)

and *Lats1/2* CKO mice (Figure 3B). We found that PCs isolated from *Lats1/2* CKO mice exhibited greater variability in the spontaneous Ca^{2+} transient rates and presented with an overall reduced frequency of spontaneous firing (Figure 3C–3F). No obvious difference was observed in the amplitude of the caffeine-induced Ca^{2+} transients between control and *Lats1/2* CKO PCs (Figure 3C–3D), indicating that the control and *Lats1/2* CKO PCs have similar SR Ca^{2+} content. However, compared with controls, PCs isolated from *Lats1/2* CKO hearts had weaker activity and decreased response to caffeine challenge (Figure 3C–3D). Quantification of spontaneous Ca^{2+} transient rates (Figure 3E) and distribution of spontaneous Ca^{2+} transient rates (Figure 3F) in isolated PCs of control and *Lats1/2* CKO mice further indicated the irregular and overall reduced frequency of spontaneous firing. These data revealed that *Lats1/2* deficiency disrupted PC Ca^{2+} activity, suggesting a critical role of *Lats1/2* in maintaining PC Ca^{2+} homeostasis.

***Lats1/2* maintains SAN homeostasis through the canonical Hippo-Yap/Taz pathway**

To determine whether Yap/Taz, the downstream effectors of *Lats1/2*, were critical for SAN homeostasis, we specifically deleted *Yap/Taz* in the CCS of *Lats1/2* CKO mice by generating *Hcn4^{CreERT2}; Lats1/2^{fl/fl}; Yap/Taz^{fl/fl}* mice. After tamoxifen injection, we confirmed ablation of *Yap/Taz* in *Lats1/2* CKO mice by the reduction in pYap immunofluorescence (IF) staining (Figure 4A–4C). Just as *Lats1/2* deficiency caused no obvious cardiac structure and function changes in the CCS, *Yap* and *Taz* deletion in the CCS of *Lats1/2* CKO did not alter cardiac structure, contractile function and SAN PC size (Figure S3). Notably, ablation of *Yap/Taz* in *Lats1/2* CKO mice rescued cardiac arrhythmias observed in *Lats1/2* CKO mice to an extent comparable to that of control mice (Figure 4D–4K). These results suggested that restriction of Yap/Taz activity by *Lats1/2* kinases-mediated phosphorylation was essential for SAN homeostasis. Masson's Trichrome staining showed that SAN fibrosis was suppressed in *Hcn4^{CreERT2}; Lats1/2^{fl/fl}; Yap/Taz^{fl/fl}* mice compared to *Lats1/2* CKO mice (Figure 5A–5C). We also observed reduced levels of Coll1a1 and vimentin immunostaining in SANs of *Hcn4^{CreERT2}; Lats1/2^{fl/fl}; Yap/Taz^{fl/fl}* mice compared with *Lats1/2* CKO mice (Figure 5D–5I).

To test whether the ablation of *Yap/Taz* inhibited proliferation of fibroblasts in the SAN, we injected EdU in control, *Lats1/2* CKO, and *Hcn4^{CreERT2}; Lats1/2^{fl/fl}; Yap/Taz^{fl/fl}* mice. In SANs of *Hcn4^{CreERT2}; Lats1/2^{fl/fl}; Yap/Taz^{fl/fl}* mice, vimentin-positive fibroblasts showed less EdU incorporation than those in SANs of *Lats1/2* CKOs, while *Yap/Taz* deletion rescued EdU-positive fibroblasts in SANs to a level comparable with that in the control mice (Figure 5G–5I). Taken together, these data indicated that *Lats1/2* in the CCS function through the canonical Hippo signaling pathway mediated by Yap/Taz.

Yap regulates genes essential for intercellular communication, cell-cell adhesion, and calcium homeostasis

To decipher molecular mechanisms underlying cardiac arrhythmias and to identify the downstream targets of the Hippo-Yap pathway involved in SAN homeostasis, we performed CUT&Tag sequencing³³ in SANs of control and *Lats1/2* CKO mice using antibodies against Yap1, H3K4me3 (as positive control), and IgG (as negative control) (Figure 6A). The heatmaps showed significantly enriched Yap binding sites in *Lats1/2* CKOs when compared

to controls (Figure 6A). H3K4me3 marks, indicative of active gene expression,⁵⁴ were significantly greater in Yap binding sites from *Lats1/2* CKO than in those from control (Figure S4A), suggesting that Yap in *Lats1/2* CKO SANs interacts with promoters/enhancers that are more transcriptionally active. We further examined genomic occupancy by Yap, and found that in control SANs, Yap binding peaks were preferentially located in intergenic and intronic regions, whereas a small fraction of Yap binding peaks were located in promoter, untranslated region (UTR), and exonic regions (Figure 6B). Yap binding peaks in *Lats1/2* CKOs were still preferentially located in intergenic and intronic regions, but a higher percentage of peaks were detected in promoter and exonic regions of *Lats1/2* CKOs than in those of controls (Figure 6B). When we overlapped and compared Yap binding peaks in controls and *Lats1/2* CKOs, we found that Yap binding peaks that exhibited significant differences still had the majority of their genomic occupancy in intergenic and intronic regions, but further increased their genomic occupancy in promoter, exonic, and UTR regions (Figure 6B). Motif analysis of YAP CUT&Tag peaks showed 35 known motifs that were specifically enriched in *Lats1/2* CKO (Figure 6C). Notably, TEAD4 (TEA Domain Transcription Factor 4) binding motif is shown among them in *Lats1/2* CKO (Figure 6C). TEAD4 is a transcription factor which contains a C-terminal YAP-binding domain⁵⁵ to interact with Yap and form a transcriptional complex for the regulation of gene expression. We further performed gene ontology (GO) term analysis of genes associated with Yap binding peaks that were significantly changed in *Lats1/2* CKOs compared with controls. The top GO terms revealed that Yap-bound genes were involved in cell-cell communication, cell-cell adhesion, calcium ion activity, cell proliferation, action potential and rhythmic process (Figure 6D).

Yap regulates the expression of *Ryr2* and TGF- β family members

Because of the molecular phenotypes observed in *Lats1/2* CKO mice, including disruption of Ca²⁺ homeostasis in PCs and enhanced fibroblast proliferation in the SAN, we visualized enriched Yap binding peaks of genes reported to regulate these events. CUT&Tag seq data suggested that Yap potentially regulates many genes that function in cell-cell communication and response to calcium ion regulation. For instance, Yap binding peaks were identified in different genomic regions of the key calcium regulator *Ryr2* (encoding RyR2, the major component of the SR Ca²⁺ channel) (Figure 6E–6F) and the paracrine fibrosis inducers *Tgfb1* and *Tgfb3* (encoding the profibrotic signaling factors TGF-beta ligands TGF- β 1 and TGF- β 3) (Figure 6G–6H), suggesting their potential regulation by Yap. Importantly, multiple alignment sequence analysis indicated that overall, the Yap binding peaks at *Ryr2*, *Tgfb1*, and *Tgfb3* genes were evolutionarily conserved among vertebrate species including humans (Figure S4B–S4D).

We further evaluated whether expression of these genes is regulated by Yap. We performed fluorescence in situ hybridization by using RNAscope for *Tgfb1* and found that *Tgfb1* transcripts were significantly increased in the SAN in *Lats1/2* CKOs compared with controls (Figure 7A–7C). Consistently, IF staining showed that the phosphorylated Smad3 (pSmad3, an indicator of TGF- β pathway activation) signal was increased in *Lats1/2* CKO SANs compared with control SANs (Figure 7D–7E, S5A–S5B), and *Yap/Taz* deletion in *Lats1/2* CKO SANs rescued pSmad3 to a level comparable with that in control SANs (Figure S5C).

qRT-PCR analysis indicated that expression of *Tgf-β1* (Figure 7F) and *Tgf-β3* (Figure 7G) was significantly upregulated, whereas expression of *Ryr2* was significantly downregulated (Figure 7K) in *Lats1/2* CKO SANs compared with control SANs. Western blot (WB) analyses confirmed greater pSmad3 levels in *Lats1/2* CKO SANs (Figure 7J), further confirming that *Lats1/2* deletion enhanced TGF-β signaling in the SAN. Consistently, the results of WB and IHC showed less RyR2 in *Lats1/2* CKO SANs (Figure 7H–7J). In summary, Yap in the SAN PCs likely functions as an activator of *Tgf-β* and a repressor of *Ryr2*.

TGF-β inhibitor treatment partially rescues the fibroblast phenotype in *Lats1/2* CKO SANs

Because the increased fibrosis and fibroblast proliferation phenotypes observed in *Lats1/2* CKO mice may be mediated partially through increased TGF-β signaling, we further evaluated this possibility by treating *Lats1/2* CKO mice with SB431542, a TGF-β1 receptor inhibitor. *Lats1/2* CKO mice were injected with SB431542 and compared with DMSO-treated *Lats1/2* CKO mice and control mice. Although *Lats1/2* CKO mice treated with SB431542 (Figure 7N) still showed increased pSmad3 signals compared with control mice (Figure 7L), those pSmad3 signals were greatly reduced compared with *Lats1/2* CKO mice treated with DMSO (Figure 7M), indicating an efficient inhibition of TGF-β signaling by SB431542. To test whether TGF-β inhibitor treatment hindered the proliferation of fibroblasts in the SAN, we injected EdU in control mice, *Lats1/2* CKO mice treated with DMSO, and *Lats1/2* CKO mice treated with SB431542. Significantly more vimentin⁺EdU⁺ proliferating fibroblasts were observed in SANs of *Lats1/2* CKO mice (Figure 7P) than in SANs of control mice (Figure 7O), while treatment with TGF-β inhibitor rescued this fibroblast phenotype (Figure 7Q–7R). Together, these data further suggested that blocking TGF-β signaling in *Lats1/2* CKO mice inhibits *Lats1/2* deficiency induced fibroblast proliferation in the SAN.

Yap regulation varies in different cardiac contexts and at different ages

To gain more insight into Yap regulation, we also performed a comprehensive comparative analysis of our Yap CUT&Tag seq data from adult mouse SANs, with published ATAC-seq datasets including PCs and right atrial cardiomyocytes (RACM) from neonatal mouse hearts,⁴¹ as well as human embryonic stem cell–derived SAN-like pacemaker cells (SANLPCs) and ventricle-like cardiomyocytes (VLCM).⁴² We checked all Yap peaks identified from CUT&Tag sequencing and mapped them to ATAC-seq at a genome-wide level. We found that overall, Yap peaks frequently coincide with the ATAC-seq peaks in all ATAC-seq datasets, suggesting that Yap binding is associated with increased chromatin accessibility at a genome-wide level (Figure S6A–S6B). However, chromatin accessibility and Yap binding activity varied among different ATAC-seq datasets (Figure S6A–S6B). As shown in the alignment of adult mouse SAN Yap CUT&Tag data with neonatal mouse PC ATAC-seq datasets (Figure S7A–S7C), Yap interaction with chromatin varies at different ages. Although some overlap occurred between Yap binding sites and accessible chromatin regions (examples are shown in red-boxed regions) in *Ryr2* (Figure S7A), *Tgfb1* (Figure S7B), and *Tgfb3* (Figure S7C), variability and differential binding events also occurred (examples are shown in green-boxed regions in Figure S7A–S7C). We also converted human SANLPC and VLCM ATAC-seq datasets by using CrossMap (0.6.1) and aligned them

with mouse Yap CUT&Tag data. For examples, Yap binding peaks at *Ryr2* (Figure S8A), *Tgfb1* (Figure S8B), and *Tgfb3* (Figure S8C) regulatory elements varied between PCs and ventricular myocytes (green-boxed regions), with some overlapping peaks (red-boxed regions). Together, these findings suggested that Yap regulation is complicated and varies in different cardiac contexts and at different ages.

DISCUSSION

In this study, we discovered that the CCS-specific deletion of *Lats1/2* causes SND and elucidated the mechanisms associated with SND due to *Lats1/2* deficiency (Figure 8). Our results indicated that altered Ca^{2+} homeostasis in SAN PCs and fibrotic remodeling in the SAN are likely causes of SND in *Lats1/2* CKO mice. Using CUT&Tag sequencing, we found that Yap potentially regulates genes involved in cell communication and adhesion, as well as in calcium homeostasis. We further found that the reduced expression of the calcium-handling protein RyR2 in the SAN and increased expression of the secreted proteins TGF- β 1 and TGF- β 3 were likely causes of SND in the context of CCS-specific *Lats1/2* deficiency. Moreover, using a double-knockout strategy, we showed that the CCS-specific deletion of *Yap/Taz* rescued SND and SND-associated fibrotic remodeling caused by *Lats1/2* deficiency. Altogether, our study provided the first evidence of an essential role for canonical Hippo signaling in the homeostatic maintenance of the SAN.

Although accumulating evidence suggests that Hippo signaling plays pivotal roles in heart development, disease, and regeneration, no other study has provided insight into Hippo signaling in the SAN. The SAN is composed of clusters of PCs controlling heart rhythm. PCs are encompassed by the extracellular matrix, which is required for electrically insulating PCs to maintain regular heartbeats.⁹ However, excessive fibrosis can block the propagation of pacemaking activity initiated from the PCs.^{9, 56} Our study reveals that *Lats1/2* deficiency in the SAN led to increased fibrosis in the SAN, which could impair electrical conduction both within the SAN and from the SAN to the surrounding atrium. Hippo signaling was previously reported to play an essential role in the transition of epicardial cells to CFs during CF development.⁵⁷ Deletion of *Lats1/2* in adult CFs resulted in CF proliferation and spontaneous self-sustaining fibrosis.³⁰ Previous work also showed that paracrine signaling may be one of the mechanisms of fibroblast-induced PC dysfunction^{58, 59} and that *Tgfb2/3* are transcriptional targets of Yap/Taz.⁶⁰ Loss of *Lats1/2* in primary hepatoblasts increases biliary epithelial cell and fibroblast proliferation by upregulating TGF- β signaling during and after liver development.⁶¹ In our study, because *Lats1/2* were ablated only in SAN PCs in *Lats1/2* CKO mice, it is likely that the upregulation of *Tgfb1* and *Tgfb3* in PCs led to an increased release of the fibrosis inducers TGF- β 1 and TGF- β 3. Evidence of TGF- β pathway activation was demonstrated by increased levels of pSmad, ultimately promoting fibrotic remodeling and fibroblast proliferation. In addition to increased pSmad in PCs, increased pSmad was detected in fibroblasts in the SAN, which is an interesting non-cell-autonomous effect caused by Hippo signaling deletion. Importantly, treatment with TGF- β 1 receptor inhibitor efficiently inhibited fibroblast proliferation in the SAN of *Lats1/2* CKOs, suggesting that *Lats1/2* deficiency caused fibroblast proliferation in the SAN through the activation of TGF- β signaling. Here, we have dissected the mechanistic regulation of SAN homeostasis by

Lats1/2; however, given the complexity of the CCS, potential roles of *Lats1/2* in other components of the CCS should be further investigated in future studies.

We also showed that *Lats1/2* function through the canonical Yap/Taz-mediated Hippo pathway in the SAN. Blocking Hippo signaling in cardiomyocytes can activate Yap to reduce fibrosis and promote heart regeneration after injury or under pathologic conditions such as myocardial infarction¹⁸ or heart failure in mice.²⁰ In contrast, under physiologic conditions, induction of YAP5SA (an active version of YAP) in cardiomyocytes did not induce interstitial fibrosis in adult mice.⁶² Notably, one month of YAP overexpression in cardiomyocytes did not induce measurable fibrosis; however, four months of overexpression caused a slight but statistically significant increase in myocardial fibrosis.⁶³ These findings suggested the complexity of fibrosis in response to Hippo signaling under different pathologic and physiologic conditions. Further, the Yap/Taz/Tea complex commonly interacts with other transcription factors to regulate gene expression in different contexts. For instance, in breast cancer cells, Yap/Taz/Tea bind to chromatin with activator protein-1 (ap-1) at composite cis-regulatory elements (CREs) containing Tea and ap-1 motifs.⁶⁴ In two recent studies, ATAC-seq data showing the mouse and human chromatin accessibility landscape of PCs and cardiomyocytes revealed SAN-specific CREs containing Tbx3, Isl1, and Shox2 motifs.^{41, 42} The possibility remains that the Yap/Taz/Tea transcription complex can interact with SAN-specific transcription factors to regulate gene expression in the SAN. Our comprehensive comparative analysis of these published ATAC-seq datasets and our Yap CUT&Tag seq data (Figure S6–S8) suggested that Yap regulation varies in PCs and cardiomyocytes, as well as in PCs from mice of different ages. Yap regulation is an interesting yet complicated area of study worthy of more in-depth investigation in the future.

Intracellular calcium concentration is a critical regulator of cardiomyocyte function.^{65, 66} For the spontaneous firing of PCs, automaticity essentially relies on the integrated activity of SR Ca²⁺ release, voltage-gated ionic currents, and Ca²⁺ pumps/transporters.^{52, 53, 67, 68} Our CUT&Tag data suggested potential Yap target genes regulating calcium ion activity and the I_f-dependent voltage membrane clock, such as *Camk2* genes (encoding CaMKII, calcium/calmodulin-dependent protein kinase II). CaMKII is a serine/threonine-specific protein kinase,^{69, 70} which also regulates Ca²⁺ homeostasis in SAN cells.⁷¹ CaMKII can catalyze the phosphorylation of RYR2,⁷² increasing Ca²⁺ release from phosphorylated RYR2. Increased oxidized CaMKII in the SAN induced by angiotensin II led to SAN cell apoptosis and SND.⁷³ Recently, Hippo-Yap signaling has been implicated in calcium homeostasis. In cardiomyocytes, several studies indicated that Yap/Tea can function as direct transcriptional activators of sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase-2a (SERCA2a), which is required for SR calcium cycling.^{74–76} An in vitro study identified the calcium channel PIEZO1 as a transcriptional target of YAP in oral squamous cell carcinoma cells.⁷⁷ However, the role of Hippo signaling in calcium activity regulation remains largely unknown. In this study, we discovered that Hippo signaling maintains the spontaneous firing rate and calcium activity of PCs. PCs in the SAN of *Lats1/2*CKO mice showed abnormal calcium activity compared with controls. Here, we determined that *Ryr2* was decreased in the SAN consequent to *Lats1/2* deletion. Consistent with our findings, the Ryr-specific inhibitor ryanodine inhibited the beating rate of PCs.⁷⁸ In addition, *Ryr2* was found to be downregulated in cardiomyocytes overexpressing YAP5SA (a constitutively active Yap)

SAN	sinoatrial node/sinus node
AVN	atrioventricular node
CUT&Tag	cleavage under targets and tagmentation
PCs	pacemaker cells
CFs	cardiac fibroblasts
SND	sinus node dysfunction
TEADs	TEA domain transcription factor family members
SR	sarcoplasmic reticulum
Ryr2	ryanodine receptor type 2
Tgfb	transforming growth factor beta
WGA	wheat germ agglutinin
EdU	5-ethynyl-2'-deoxyuridine
cTnT	cardiac troponin-T
Vim	vimentin
Coll1a1	collagen 1
Acta2/aSMA	alpha-smooth muscle actin
Postn	Periostin
GO	gene ontology

References

1. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. *The Journal of clinical investigation*. 2005;115:2305–2315 [PubMed: 16138184]
2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. *The New England journal of medicine*. 2001;345:1473–1482 [PubMed: 11794197]
3. Mandla R, Jung C, Vedantham V. Transcriptional and epigenetic landscape of cardiac pacemaker cells: Insights into cellular specialization in the sinoatrial node. *Frontiers in physiology*. 2021;12:712666 [PubMed: 34335313]
4. Christoffels VM, Smits GJ, Kispert A, Moonman AF. Development of the pacemaker tissues of the heart. *Circulation research*. 2010;106:240–254 [PubMed: 20133910]
5. van Eif VWW, Devalla HD, Boink GJJ, Christoffels VM. Transcriptional regulation of the cardiac conduction system. *Nature reviews. Cardiology*. 2018;15:617–630 [PubMed: 29875439]
6. Linscheid N, Logantha S, Poulsen PC, Zhang S, Schrolkamp M, Egerod KL, Thompson JJ, Kitmitto A, Galli G, Humphries MJ, Zhang H, Pers TH, Olsen JV, Boyett M, Lundby A. Quantitative proteomics and single-nucleus transcriptomics of the sinus node elucidates the foundation of cardiac pacemaking. *Nature communications*. 2019;10:2889
7. Kashou AH, Basit H, Chhabra L. *Physiology, sinoatrial node*. Statpearls. Treasure Island (FL); 2021.

8. Liang X, Evans SM, Sun Y. Development of the cardiac pacemaker. Cellular and molecular life sciences : CMLS. 2017;74:1247–1259 [PubMed: 27770149]
9. Csepe TA, Kalyanasundaram A, Hansen BJ, Zhao J, Fedorov VV. Fibrosis: A structural modulator of sinoatrial node physiology and dysfunction. Frontiers in physiology. 2015;6:37 [PubMed: 25729366]
10. Li N, Hansen BJ, Csepe TA, Zhao J, Ignozzi AJ, Sul LV, Zakharkin SO, Kalyanasundaram A, Davis JP, Biesiadecki BJ, Kilic A, Janssen PML, Mohler PJ, Weiss R, Hummel JD, Fedorov VV. Redundant and diverse intranodal pacemakers and conduction pathways protect the human sinoatrial node from failure. Science translational medicine. 2017;9
11. Zhang H, Sun AY, Kim JJ, Graham V, Finch EA, Nepliouev I, Zhao G, Li T, Lederer WJ, Stiber JA, Pitt GS, Bursac N, Rosenberg PB. Stim1-ca2+ signaling modulates automaticity of the mouse sinoatrial node. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:E5618–5627 [PubMed: 26424448]
12. Yavari A, Bellahcene M, Bucchi A, Sirenko S, Pinter K, Herring N, Jung JJ, Tarasov KV, Sharpe EJ, Wolfien M, Czibik G, Steeples V, Ghaffari S, Nguyen C, Stockenhuber A, Clair JRS, Rimbach C, Okamoto Y, Yang D, Wang M, Ziman BD, Moen JM, Riordon DR, Ramirez C, Paina M, Lee J, Zhang J, Ahmet I, Matt MG, Tarasova YS, Baban D, Sahgal N, Lockstone H, Puliyadi R, de Bono J, Siggs OM, Gomes J, Muskett H, Maguire ML, Beglov Y, Kelly M, Dos Santos PPN, Bright NJ, Woods A, Gehmlich K, Isackson H, Douglas G, Ferguson DJP, Schneider JE, Tinker A, Wolkenhauer O, Channon KM, Cornall RJ, Sternick EB, Paterson DJ, Redwood CS, Carling D, Proenza C, David R, Baruscotti M, DiFrancesco D, Lakatta EG, Watkins H, Ashrafian H. Mammalian gamma2 ampk regulates intrinsic heart rate. Nat Commun. 2017;8:1258 [PubMed: 29097735]
13. Easterling M, Rossi S, Mazzella AJ, Bressan M. Assembly of the cardiac pacemaking complex: Electrogenic principles of sinoatrial node morphogenesis. J Cardiovasc Dev Dis. 2021;8
14. Jensen PN, Gronroos NN, Chen LY, Folsom AR, deFilippi C, Heckbert SR, Alonso A. Incidence of and risk factors for sick sinus syndrome in the general population. J Am Coll Cardiol. 2014;64:531–538 [PubMed: 25104519]
15. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, Lai ZC, Guan KL. Tead mediates yap-dependent gene induction and growth control. Genes Dev. 2008;22:1962–1971 [PubMed: 18579750]
16. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL. Tead transcription factors mediate the function of taz in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009;284:13355–13362 [PubMed: 19324877]
17. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, Martin JF. Hippo pathway inhibits wnt signaling to restrain cardiomyocyte proliferation and heart size. Science. 2011;332:458–461 [PubMed: 21512031]
18. Heallen T, Morikawa Y, Leach J, Tao G, Willerson JT, Johnson RL, Martin JF. Hippo signaling impedes adult heart regeneration. Development. 2013;140:4683–4690 [PubMed: 24255096]
19. Xin M, Kim Y, Sutherland LB, Murakami M, Qi X, McAnally J, Porrello ER, Mahmoud AI, Tan W, Shelton JM, Richardson JA, Sadek HA, Bassel-Duby R, Olson EN. Hippo pathway effector yap promotes cardiac regeneration. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:13839–13844 [PubMed: 23918388]
20. Leach JP, Heallen T, Zhang M, Rahmani M, Morikawa Y, Hill MC, Segura A, Willerson JT, Martin JF. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature. 2017;550:260–264 [PubMed: 28976966]
21. Morikawa Y, Zhang M, Heallen T, Leach J, Tao G, Xiao Y, Bai Y, Li W, Willerson JT, Martin JF. Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in hippo-deficient mice. Science signaling. 2015;8:ra41 [PubMed: 25943351]
22. Wang J, Liu S, Heallen T, Martin JF. The hippo pathway in the heart: Pivotal roles in development, disease, and regeneration. Nat Rev Cardiol. 2018
23. Zheng M, Jacob J, Hung SH, Wang J. The hippo pathway in cardiac regeneration and homeostasis: New perspectives for cell-free therapy in the injured heart. Biomolecules. 2020;10

24. Chen SN, Gurha P, Lombardi R, Ruggiero A, Willerson JT, Marian AJ. The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. *Circulation research*. 2014;114:454–468 [PubMed: 24276085]
25. Wang P, Mao B, Luo W, Wei B, Jiang W, Liu D, Song L, Ji G, Yang Z, Lai YQ, Yuan Z. The alteration of hippo/yap signaling in the development of hypertrophic cardiomyopathy. *Basic Res Cardiol*. 2014;109:435 [PubMed: 25168380]
26. Li N, Artiga E, Kalyanasundaram A, Hansen BJ, Webb A, Pietrzak M, Biesiadecki B, Whitson B, Mokadam NA, Janssen PML, Hummel JD, Mohler PJ, Dobrzynski H, Fedorov VV. Altered microrna and mrna profiles during heart failure in the human sinoatrial node. *Scientific reports*. 2021;11:19328 [PubMed: 34588502]
27. Yu SD, Yu JY, Guo Y, Liu XY, Liang T, Chen LZ, Chu YP, Zhang HP. Bioinformatic analysis for the identification of potential gene interactions and therapeutic targets in atrial fibrillation. *European review for medical and pharmacological sciences*. 2021;25:2281–2290 [PubMed: 33755965]
28. Liang X, Wang G, Lin L, Lowe J, Zhang Q, Bu L, Chen Y, Chen J, Sun Y, Evans SM. Hcn4 dynamically marks the first heart field and conduction system precursors. *Circulation research*. 2013;113:399–407 [PubMed: 23743334]
29. Wang J, Bai Y, Li N, Ye W, Zhang M, Greene SB, Tao Y, Chen Y, Wehrens XH, Martin JF. Pitx2-microrna pathway that delimits sinoatrial node development and inhibits predisposition to atrial fibrillation. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111:9181–9186 [PubMed: 24927531]
30. Xiao Y, Hill MC, Li L, Deshmukh V, Martin TJ, Wang J, Martin JF. Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis. *Genes Dev*. 2019;33:1491–1505 [PubMed: 31558567]
31. Sharpe EJ, St Clair JR, Proenza C. Methods for the isolation, culture, and functional characterization of sinoatrial node myocytes from adult mice. *Journal of visualized experiments : JoVE*. 2016
32. Chiang DY, Kongchan N, Beavers DL, Alsina KM, Voigt N, Neilson JR, Jakob H, Martin JF, Dobrev D, Wehrens XH, Li N. Loss of microrna-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release. *Circulation. Arrhythmia and electrophysiology*. 2014;7:1214–1222 [PubMed: 25389315]
33. Kaya-Okur HS, Janssens DH, Henikoff JG, Ahmad K, Henikoff S. Efficient low-cost chromatin profiling with cut&tag. *Nature protocols*. 2020;15:3264–3283 [PubMed: 32913232]
34. Langmead B, Salzberg SL. Fast gapped-read alignment with bowtie 2. *Nature methods*. 2012;9:357–359 [PubMed: 22388286]
35. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S. The sequence alignment/map format and samtools. *Bioinformatics*. 2009;25:2078–2079 [PubMed: 19505943]
36. Ramirez F, Ryan DP, Gruning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dundar F, Manke T. Deeptools2: A next generation web server for deep-sequencing data analysis. *Nucleic acids research*. 2016;44:W160–165 [PubMed: 27079975]
37. Meers MP, Tenenbaum D, Henikoff S. Peak calling by sparse enrichment analysis for cut&run chromatin profiling. *Epigenetics & chromatin*. 2019;12:42 [PubMed: 31300027]
38. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and b cell identities. *Molecular cell*. 2010;38:576–589 [PubMed: 20513432]
39. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nature communications*. 2019;10:1523
40. Margulies EH, Blanchette M, Program NCS, Haussler D, Green ED. Identification and characterization of multi-species conserved sequences. *Genome research*. 2003;13:2507–2518 [PubMed: 14656959]

41. Galang G, Mandla R, Ruan H, Jung C, Sinha T, Stone NR, Wu RS, Mannion BJ, Allu PKR, Chang K, Rammohan A, Shi MB, Pennacchio LA, Black BL, Vedantham V. Atac-seq reveals an *isl1* enhancer that regulates sinoatrial node development and function. *Circulation research*. 2020;127:1502–1518 [PubMed: 33044128]
42. van Eif VWW, Protze SI, Bosada FM, Yuan X, Sinha T, van Duijvenboden K, Ernault AC, Mohan RA, Wakker V, de Gier-de Vries C, Hooijkaas IB, Wilson MD, Verkerk AO, Bakkers J, Boukens BJ, Black BL, Scott IC, Christoffels VM. Genome-wide analysis identifies an essential human *tbx3* pacemaker enhancer. *Circulation research*. 2020;127:1522–1535 [PubMed: 33040635]
43. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC, Guan KL. Inactivation of *yap* oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. *Genes Dev*. 2007;21:2747–2761 [PubMed: 17974916]
44. Huang J, Wu S, Barrera J, Matthews K, Pan D. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating *yorkie*, the *drosophila* homolog of *yap*. *Cell*. 2005;122:421–434 [PubMed: 16096061]
45. Halder G, Johnson RL. Hippo signaling: Growth control and beyond. *Development*. 2011;138:9–22 [PubMed: 21138973]
46. Ludwig A, Zong X, Jeglitsch M, Hofmann F, Biel M. A family of hyperpolarization-activated mammalian cation channels. *Nature*. 1998;393:587–591 [PubMed: 9634236]
47. Stieber J, Herrmann S, Feil S, Loster J, Feil R, Biel M, Hofmann F, Ludwig A. The hyperpolarization-activated channel *hcn4* is required for the generation of pacemaker action potentials in the embryonic heart. *Proceedings of the National Academy of Sciences of the United States of America*. 2003;100:15235–15240 [PubMed: 14657344]
48. Moorman AF, Christoffels VM. Cardiac chamber formation: Development, genes, and evolution. *Physiological reviews*. 2003;83:1223–1267 [PubMed: 14506305]
49. Matsui Y, Nakano N, Shao D, Gao S, Luo W, Hong C, Zhai P, Holle E, Yu X, Yabuta N, Tao W, Wagner T, Nojima H, Sadoshima J. *Lats2* is a negative regulator of myocyte size in the heart. *Circulation research*. 2008;103:1309–1318 [PubMed: 18927464]
50. Xin M, Kim Y, Sutherland LB, Qi X, McAnally J, Schwartz RJ, Richardson JA, Bassel-Duby R, Olson EN. Regulation of insulin-like growth factor signaling by *yap* governs cardiomyocyte proliferation and embryonic heart size. *Sci Signal*. 2011;4:ra70 [PubMed: 22028467]
51. Del Re DP, Matsuda T, Zhai P, Gao S, Clark GJ, Van Der Weyden L, Sadoshima J. Proapoptotic *rassf1a/mst1* signaling in cardiac fibroblasts is protective against pressure overload in mice. *The Journal of clinical investigation*. 2010;120:3555–3567 [PubMed: 20890045]
52. Lakatta EG, Maltsev VA, Vinogradova TM. A coupled system of intracellular ca^{2+} clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. *Circulation research*. 2010;106:659–673 [PubMed: 20203315]
53. Mangoni ME, Nargeot J. Genesis and regulation of the heart automaticity. *Physiological reviews*. 2008;88:919–982 [PubMed: 18626064]
54. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. *Cell*. 2007;129:823–837 [PubMed: 17512414]
55. Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, Song H. Structural basis of *yap* recognition by *tead4* in the hippo pathway. *Genes Dev*. 2010;24:290–300 [PubMed: 20123908]
56. Glukhov AV, Hage LT, Hansen BJ, Pedraza-Toscano A, Vargas-Pinto P, Hamlin RL, Weiss R, Carnes CA, Billman GE, Fedorov VV. Sinoatrial node reentry in a canine chronic left ventricular infarct model: Role of intranodal fibrosis and heterogeneity of refractoriness. *Circulation. Arrhythmia and electrophysiology*. 2013;6:984–994 [PubMed: 23960214]
57. Xiao Y, Hill MC, Zhang M, Martin TJ, Morikawa Y, Wang S, Moise AR, Wythe JD, Martin JF. Hippo signaling plays an essential role in cell state transitions during cardiac fibroblast development. *Dev Cell*. 2018;45:153–169 e156 [PubMed: 29689192]
58. Munoz V, Campbell K, Shibayama J. Fibroblasts: Modulating the rhythm of the heart. *The Journal of physiology*. 2008;586:2423–2424 [PubMed: 18356197]

59. Fahrenbach JP, Mejia-Alvarez R, Banach K. The relevance of non-excitabile cells for cardiac pacemaker function. *The Journal of physiology*. 2007;585:565–578 [PubMed: 17932143]
60. Nishio M, Sugimachi K, Goto H, Wang J, Morikawa T, Miyachi Y, Takano Y, Hikasa H, Itoh T, Suzuki SO, Kurihara H, Aishima S, Leask A, Sasaki T, Nakano T, Nishina H, Nishikawa Y, Sekido Y, Nakao K, Shin-Ya K, Mimori K, Suzuki A. Dysregulated yap1/taz and tgf-beta signaling mediate hepatocarcinogenesis in mob1a/1b-deficient mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113:E71–80 [PubMed: 26699479]
61. Lee DH, Park JO, Kim TS, Kim SK, Kim TH, Kim MC, Park GS, Kim JH, Kuninaka S, Olson EN, Saya H, Kim SY, Lee H, Lim DS. Lats-yap/taz controls lineage specification by regulating tgfbeta signaling and hnf4alpha expression during liver development. *Nature communications*. 2016;7:11961
62. Monroe TO, Hill MC, Morikawa Y, Leach JP, Heallen T, Cao S, Krijger PHL, de Laat W, Wehrens XHT, Rodney GG, Martin JF. Yap partially reprograms chromatin accessibility to directly induce adult cardiogenesis in vivo. *Dev Cell*. 2019;48:765–779 e767 [PubMed: 30773489]
63. Lin Z, von Gise A, Zhou P, Gu F, Ma Q, Jiang J, Yau AL, Buck JN, Gouin KA, van Gorp PR, Zhou B, Chen J, Seidman JG, Wang DZ, Pu WT. Cardiac-specific yap activation improves cardiac function and survival in an experimental murine mi model. *Circulation research*. 2014;115:354–363 [PubMed: 24833660]
64. Zanonato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, Rosato A, Bicciato S, Cordenonsi M, Piccolo S. Genome-wide association between yap/taz/tead and ap-1 at enhancers drives oncogenic growth. *Nature cell biology*. 2015;17:1218–1227 [PubMed: 26258633]
65. Fearnley CJ, Roderick HL, Bootman MD. Calcium signaling in cardiac myocytes. *Cold Spring Harbor perspectives in biology*. 2011;3:a004242 [PubMed: 21875987]
66. Eisner DA, Caldwell JL, Kistamas K, Trafford AW. Calcium and excitation-contraction coupling in the heart. *Circulation research*. 2017;121:181–195 [PubMed: 28684623]
67. DiFrancesco D The role of the funny current in pacemaker activity. *Circulation research*. 2010;106:434–446 [PubMed: 20167941]
68. Sah R, Mesirca P, Van den Boogert M, Rosen J, Mably J, Mangoni ME, Clapham DE. Ion channel-kinase trpm7 is required for maintaining cardiac automaticity. *Proceedings of the National Academy of Sciences of the United States of America*. 2013;110:E3037–3046 [PubMed: 23878236]
69. Schulman H, Greengard P. Stimulation of brain membrane protein phosphorylation by calcium and an endogenous heat-stable protein. *Nature*. 1978;271:478–479 [PubMed: 628428]
70. Lisman J, Schulman H, Cline H. The molecular basis of camkii function in synaptic and behavioural memory. *Nature reviews. Neuroscience*. 2002;3:175–190 [PubMed: 11994750]
71. Vinogradova TM, Zhou YY, Bogdanov KY, Yang D, Kuschel M, Cheng H, Xiao RP. Sinoatrial node pacemaker activity requires ca(2+)/calmodulin-dependent protein kinase ii activation. *Circulation research*. 2000;87:760–767 [PubMed: 11055979]
72. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase ii phosphorylation regulates the cardiac ryanodine receptor. *Circulation research*. 2004;94:e61–70 [PubMed: 15016728]
73. Swaminathan PD, Purohit A, Soni S, Voigt N, Singh MV, Glukhov AV, Gao Z, He BJ, Luczak ED, Joiner ML, Kutschke W, Yang J, Donahue JK, Weiss RM, Grumbach IM, Ogawa M, Chen PS, Efimov I, Dobrev D, Mohler PJ, Hund TJ, Anderson ME. Oxidized camkii causes cardiac sinus node dysfunction in mice. *The Journal of clinical investigation*. 2011;121:3277–3288 [PubMed: 21785215]
74. Liu R, Lee J, Kim BS, Wang Q, Buxton SK, Balasubramanyam N, Kim JJ, Dong J, Zhang A, Li S, Gupte AA, Hamilton DJ, Martin JF, Rodney GG, Coarfa C, Wehrens XH, Yechoor VK, Moulik M. Tead1 is required for maintaining adult cardiomyocyte function, and its loss results in lethal dilated cardiomyopathy. *JCI insight*. 2017;2
75. Zhong J, Ouyang H, Zheng S, Guo Z, Chen Y, Zhong Y, Zhong W, Zuo L, Lu J. The yap/serca2a signaling pathway protects cardiomyocytes against reperfusion-induced apoptosis. *Aging*. 2020;12:13618–13632 [PubMed: 32645692]

76. Xie J, Wang Y, Ai D, Yao L, Jiang H. The role of the hippo pathway in heart disease. *The FEBS journal*. 2021
77. Hasegawa K, Fujii S, Matsumoto S, Tajiri Y, Kikuchi A, Kiyoshima T. Yap signaling induces *piezo1* to promote oral squamous cell carcinoma cell proliferation. *The Journal of pathology*. 2021;253:80–93 [PubMed: 32985688]
78. Bogdanov KY, Vinogradova TM, Lakatta EG. Sinoatrial nodal cell ryanodine receptor and $na(+)-ca(2+)$ exchanger: Molecular partners in pacemaker regulation. *Circulation research*. 2001;88:1254–1258 [PubMed: 11420301]
79. Delgado C, Bu L, Zhang J, Liu FY, Sall J, Liang FX, Furley AJ, Fishman GI. Neural cell adhesion molecule is required for ventricular conduction system development. *Development*. 2021;148
80. Li J, Patel VV, Kostetskii I, Xiong Y, Chu AF, Jacobson JT, Yu C, Morley GE, Molkenin JD, Radice GL. Cardiac-specific loss of n-cadherin leads to alteration in connexins with conduction slowing and arrhythmogenesis. *Circulation research*. 2005;97:474–481 [PubMed: 16100040]
81. Li J, Patel VV, Radice GL. Dysregulation of cell adhesion proteins and cardiac arrhythmogenesis. *Clinical medicine & research*. 2006;4:42–52 [PubMed: 16595792]
82. van Rijen HVM, van Veen TAB, Gros D, Wilders R, de Bakker JMT. Connexins and cardiac arrhythmias. *Advances in cardiology*. 2006;42:150–160 [PubMed: 16646589]
83. Kanno S, Saffitz JE. The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. *Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology*. 2001;10:169–177 [PubMed: 11600334]
84. Severs NJ, Coppens SR, Dupont E, Yeh HI, Ko YS, Matsushita T. Gap junction alterations in human cardiac disease. *Cardiovascular research*. 2004;62:368–377 [PubMed: 15094356]
85. Arnolds DE, Chu A, McNally EM, Nobrega MA, Moskowitz IP. The emerging genetic landscape underlying cardiac conduction system function. *Birth defects research. Part A, Clinical and molecular teratology*. 2011;91:578–585 [PubMed: 21538814]
86. Lai JKH, Collins MM, Uribe V, Jimenez-Amilburu V, Gunther S, Maischein HM, Stainier D.Y.R. The hippo pathway effector *wwtr1* regulates cardiac wall maturation in zebrafish. *Development*. 2018;145
87. Dai W, Nadadur RD, Brennan JA, Smith HL, Shen KM, Gadek M, Laforest B, Wang M, Gemel J, Li Y, Zhang J, Ziman BD, Yan J, Ai X, Beyer EC, Lakata EG, Kasthuri N, Efimov IR, Broman MT, Moskowitz IP, Shen L, Weber CR. *Zo-1* regulates intercalated disc composition and atrioventricular node conduction. *Circulation research*. 2020;127:e28–e43 [PubMed: 32347164]
88. Liu X, Li H, Rajurkar M, Li Q, Cotton JL, Ou J, Zhu LJ, Goel HL, Mercurio AM, Park JS, Davis RJ, Mao J. *Tead* and *ap1* coordinate transcription and motility. *Cell reports*. 2016;14:1169–1180 [PubMed: 26832411]
89. Nardone G, Oliver-De La Cruz J, Vrbsky J, Martini C, Pribyl J, Skladal P, Pesl M, Caluori G, Pagliari S, Martino F, Maceckova Z, Hajduch M, Sanz-Garcia A, Pugno NM, Stokin GB, Forte G. Yap regulates cell mechanics by controlling focal adhesion assembly. *Nature communications*. 2017;8:15321
90. Aharonov A, Shakked A, Umansky KB, Savidor A, Genzelinakh A, Kain D, Lendengolts D, Revach OY, Morikawa Y, Dong J, Levin Y, Geiger B, Martin JF, Tzahor E. *ErbB2* drives yap activation and emt-like processes during cardiac regeneration. *Nature cell biology*. 2020;22:1346–1356 [PubMed: 33046882]
91. Kostetskii I, Li J, Xiong Y, Zhou R, Ferrari VA, Patel VV, Molkenin JD, Radice GL. Induced deletion of the n-cadherin gene in the heart leads to dissolution of the intercalated disc structure. *Circulation research*. 2005;96:346–354 [PubMed: 15662031]

Clinical Perspective

What Is New?

- We identified Hippo signaling as an important regulator of SAN homeostasis.
- Deletion of the essential Hippo kinases *Lats1/2* causes increased fibroblast proliferation and fibrosis in the SAN involving non-cell-autonomous TGF- β signaling.
- Hippo signaling regulates calcium homeostasis in pacemaker cells that may be partially mediated by the regulation of genes encoding key calcium handling proteins such as Ryr2.
- Deletion of the Hippo effectors *Yap* and *Taz* in the SAN can rescue defects caused by *Lats1/2* deficiency, revealing that the canonical Hippo signaling pathway plays vital function in SAN homeostasis.

What Are the Clinical Implications?

- Our comprehensive studies of various mouse models provide novel insight into the molecular genetic regulation of SAN homeostasis and reveal new potential therapeutic targets for recovery from cardiac arrhythmias.
- Dysregulation and genetic variants of the genes encoding Hippo signaling pathway components are associated with human arrhythmias, and here we present a preclinical model for sinus node dysfunction, which may provide mechanistic insights applicable to the treatment of patients with bradycardia disorders.




Figure 1. Inducible cardiac conduction system (CCS)-specific *Lats1/2* deletion induces cardiac arrhythmias.

A. Experimental strategy for CCS-specific Cre activation and tissue collection. Cre activity was induced with 2 consecutive intraperitoneal injections of tamoxifen. **B-C.** Representative images of immunofluorescence staining of pYap in the SAN after tamoxifen induction in control (**B**) and *Lats1/2* CKO (**C**) mice. Hcn4 (green) was used to label pacemaker cells (PCs) in the SAN. pYap (red) is an indicator of Hippo signaling activity. Nuclei were labeled with DAPI (blue). Lower panels show higher-magnification views of the boxed

areas in the upper panels. Scale bar, 25 μm and 5 μm . **D-E.** Representative images of immunofluorescence staining of aYap in the SAN after tamoxifen induction in control (**D**) and *Lats1/2* CKO (**E**) mice. aYap was stained with red; Hcn4 (green) was used to label PCs in SAN. Nuclei were labeled with DAPI (blue). Lower panels show higher-magnification views of the boxed areas in the upper panels Scale bar, 25 μm and 5 μm . **F-G.** Representative electrocardiogram (ECG) recordings in control and *Lats1/2* CKO mice. Star, irregular RR intervals (**g**); triangle, AV blocks (**g'**); arrows, abnormal P waves (**g''**). **H-I.** Representative Poincaré plots showing beat-to-beat RR interval variability from control (n=5) and *Lats1/2* CKO (n=6) mice. Each color represents individual RR/RR+1 intervals from a different mouse. **J-K.** Heart rates and RR intervals of control and *Lats1/2* CKO mice. Control, n=5; *Lats1/2* CKO, n=6. Data are shown as means \pm s.e.m. Statistical significance was determined by t-test, *p<0.05.




Figure 2. *Lats1/2* deletion in CCS results in SAN fibrosis and fibroblast proliferation. **A-B.** Masson's Trichrome staining in control and *Lats1/2*CKO SANs. Panels on the right show higher magnification of the boxed area from the panels on the left. Scale bar, 100 μ m. **C-E.** Representative immunofluorescence confocal images from control (C) and *Lats1/2*CKO (D) SANs after Hcn4-Cre activation showing collagens (Col1a1, red), PCs (Hcn4, green), and nuclei labeling (DAPI, blue). Panels on the right show higher magnification of the boxed area in panels on the left. Collagen 1 quantification (E), measured by pixel intensity. Data in (E) represent means \pm s.e.m; statistical significance was determined by

Mann–Whitney test. Scale bar, 25 μm and 5 μm . **F–H.** Representative images of EdU-labeled control (**F**) and *Lats1/2* CKO (**G**) SANs. Samples were pulse-chased with EdU (white); fibroblasts and PCs were labeled with vimentin (red) and cTnT (green) respectively. Nuclei were stained with DAPI (blue). Arrows point to EdU-positive cells. Panels on the right show higher magnification of the boxed area in panels on the left. (**H**) Quantification of fibroblast proliferation. Representative image of proliferating fibroblast cells shown in **F** and **G**. Statistical significance was determined using the Mann–Whitney test ($P < 0.05$). Scale bar, 25 μm and 5 μm . **I–L.** Quantitative real-time polymerase chain reaction validation of *Collagen 1* (**I**), *Periostin* (*Postn*) (**J**), *Vimentin* (*Vim*) (**K**), and *Acta2* (α -SMA) (**L**) in control and *Lats1/2* CKO SANs. Each dot represents an independent biological replicate ($n = 4$). Data are shown as means \pm s.e.m. Statistical significance was determined by Mann–Whitney test.




Figure 3. *Lats1/2* deficiency disrupts the calcium homeostasis of pacemaker cells.

A-D. Ca^{2+} transient recordings obtained from control (**A**, **C**) and *Lats1/2* CKO (**B**, **D**) PCs in the presence of caffeine (Caff). **A-B.** Representative confocal line-scan images. **C-D** Spatial average of fluorescence signal normalized to baseline (F/F0) over the entire field of observation of isolated PCs from control and *Lats1/2* CKO. PCs from *Lats1/2* mutant showed reduced and irregular frequency of spontaneous firing rate compared to controls. During caffeine challenge, *Lats1/2*CKO PCs also had a weaker response and reduced activity of the caffeine-induced Ca^{2+} signal compared to controls. Caff, caffeine. **E-F.** Summary data for spontaneous firing rate. **(E)** Quantification of spontaneous Ca^{2+} transient rates in SAN cells of control and *Lats1/2*CKO mice (n=12 cells/3 mice in control, n=18 cells/6 mice in *Lats1/2*CKO, P=0.036 by Student t-test). **(F)** Distribution of spontaneous Ca^{2+} transient rates in isolated PCs from control and *Lats1/2*CKO.




Figure 4. *Yap/Taz* deletion rescues arrhythmic phenotype in *Lats1/2* mutants.

A-C. Representative images of immunofluorescent staining of pYap in SAN after tamoxifen induction in control (**A**), *Lats1/2* CKO (**B**), and *Lats1/2; Yap/Taz* CKO (**C**) mice. Hcn4 (green) was used to label PCs in SAN. pYap (red) is an indicator of Hippo signaling activity. Nuclei were labeled with DAPI (blue). Panels on the right show higher magnification of the boxed area in the panels on the left. Stars, pYap staining. Scale bar, 25 μ m and 5 μ m. **D-F.** Representative ECG recordings in control (**D**), *Lats1/2* CKO (**E**), and *Lats1/2; Yap/Taz* CKO (**F**) mice. Triangle, AV blocks (**e**); star, irregular RR intervals (**e'**); arrows, abnormal P waves (**e''**). **G-I.** Representative Poincaré plots, showing beat-to-beat RR interval variability, from control (n=8), *Lats1/2* CKO (n=7) and *Lats1/2; Yap/Taz* CKO (n=5). Each color represents individual RR/RR+1 intervals from a different mouse. **J-K.** Heart rate and RR interval of control, *Lats1/2* CKO, and *Lats1/2; Yap/Taz* CKO mice. Data are shown as means \pm s.e.m.

Statistical significance was determined by one-way ANOVA analysis. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. *Yap/Taz* deletion in *Lats1/2* CKO rescues SAN fibrosis and fibroblast proliferation. A-C. Masson's Trichrome staining in control (A), *Lats1/2* CKO (B), and *Lats1/2; Yap/Taz* CKO (C) SANs. Lower panels show higher magnification of the boxed areas from the upper panels. Scale bar, 100 μm . D-F. Representative immunofluorescence confocal images of Collagen 1 (red) from control (D), *Lats1/2* CKO (E), and *Lats1/2; Yap/Taz* CKO (F) SANs. Hcn4 are stained with green, and nuclei are stained with blue. The right-hand panels show higher magnification of the boxed areas in the left-hand panels. Scale bar, 25 μm and 5 μm . G-I. Representative images of EdU-labeled control (G), *Lats1/2* CKO (H), and *Lats1/2; Yap/Taz* CKO (I) SANs. Samples were pulse-chased with EdU (white); fibroblasts and PCs were labeled with vimentin (red) and cTnT (green), respectively. Nuclei were stained with DAPI (blue). Right-hand panels show higher magnification of boxed areas in left-hand panels. Scale bar, 25 μm and 5 μm .




Figure 6. Analysis of CUT&Tag sequencing data.

A. Heatmap showing DNA binding peaks determined by CUT&Tag sequencing with Yap, IgG, and H3K4me3 in control and *Lats1/2*CKO SANS. Quantification of CUT&Tag enrichment signal by ± 1 kb to the center of Yap-associated regions. **B.** Distribution of Yap-associated regions. **C.** Motif analysis. The upper panel shows the percentage of identified binding sites containing the consensus binding motif(s). HOMER software was used to identify known motifs underneath Yap1 CUT&Tag peaks. The Tead4 consensus motif (the lower panel) was highly enriched and was represented as a sequence logo position weight

matrix. **D.** Gene ontology (GO) analysis of direct targets of Yap. **E-H.** UCSC genome browser view of Yap CUT&Tag enriched peaks for the labeled genes. Larger peaks were seen in *Lats1/2* CKO. Tead (TEA domain) motifs were also aligned.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 7. *Lats1/2* deficiency activated TGF- β signaling and inhibited Ryr2 expression in the SAN. A-C. Representative RNAscope confocal images of *Tgfb1* from control (A) and *Lats1/2* CKO (B) SANs. *Tgfb1* mRNA was stained red; the cell membrane was stained green (by using wheat germ agglutinin [WGA]), and nuclei were stained blue. *Tgfb1* mRNA quantification (C), measured by pixel intensity. Data in (C) represent means \pm s.e.m.; statistical significance was determined using the Mann–Whitney test. Scale bar, 25 μ m, 5 μ m. D-E. Representative images of immunofluorescence staining of pSmad3 in SAN after tamoxifen induction in control (D) and *Lats1/2* CKO (E) mice. Vimentin (green) was used to label fibroblasts in SAN. pSmad3 (red) is an indicator of TGF- β signaling activity. Nuclei were labeled with DAPI (blue). Right-hand panels show higher magnification of the boxed area in the left-hand panels. Arrows, pSmad3 staining in nuclei. Scale bar, 25 μ m and 5 μ m.

F-G. Quantitative real-time PCR (qRT-PCR) data indicated that expression of *Tgf-β1* (**F**) and *Tgf-β3* (**G**) was greater in *Lats1/2* CKO SAN than in control SAN. Each dot represents an independent biological replicate (n=4). Data are shown as means ± s.e.m; statistical significance was determined using the Mann–Whitney test. **H-I.** Representative images of immunofluorescence staining of Ryr2 in SAN after tamoxifen induction in control (**H**) and *Lats1/2* CKO (**I**) mice. Ryr2 was stained with red; Hcn4 (green) was used to label PCs in SAN. Nuclei were labeled with DAPI (blue). Scale bar, 25 μm and 5 μm. **J.** Representative western blot images of Ryr2, pSmad3, and corresponding GAPDH loading control. **K.** qRT-PCR data indicated that expression of *Ryr2* was decreased in *Lats1/2* CKO compared with control SAN. Each dot represents an independent biological replicate (n=4). Data are shown as means ± s.e.m. Statistical significance was determined using the Mann–Whitney test, p< 0.05. **L-N.** Representative immunofluorescence confocal images of pSmad3 from SANs of control mice (**L**), *Lats1/2* CKO mice (**M**), and *Lats1/2* CKO mice treated with SB431542 (**N**). SB431542 is a selective inhibitor of TGF-β signaling. Vimentin (Vim) is stained in green, pSmad3 is stained in red, and nuclei are stained in blue. Arrows, pSmad3 staining in nuclei. Scale bar, 25 μm. **O-R.** Representative images of EdU-labeling of SANs of control mice (**O**), *Lats1/2* CKO mice (**P**), and *Lats1/2* CKO mice treated with SB431542 (**Q**). Samples were pulse-chased with EdU (white). Fibroblasts and PCs were labeled with vimentin (red) and cTnT (green), respectively. Nuclei were stained with DAPI (blue). **R.** Quantification of fibroblast proliferation. Representative images of the experiment shown in Figure 7O–7Q. Statistical significance was determined by the Kruskal–Wallis test. Scale bar, 25 μm.




Figure 8. Schematic representation of the Hippo signaling–mediated mechanisms underlying the development of SND.

On one hand, the CCS-specific loss of *Lats1/2* (‘Hippo kinases off’) can enhance the transcription of calcium-handling protein genes such as *Ryr2* and cause the dysfunctional ‘Ca²⁺ clock’ in PCs, thereby impairing their pacemaking function. On the other hand, the upregulation of genes in the profibrotic pathway, such as *Tgf-β*, due to the CCS-specific loss of *Lats1/2* can promote fibroblast proliferation and increase fibrosis within and near the SAN, which also impairs the propagation of electrical activation from the SAN to the atrial myocardium. Figure was created with Biorender (<https://biorender.com/>).